Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Tumor
100%
Antigen-presenting Cells
100%
STI571
100%
Cell Function
100%
CD4+ T
100%
Imatinib Mesylate
100%
Cell Tolerance
100%
In Vivo Applications
50%
Therapeutic Vaccine
25%
Cancer Immunotherapy
25%
Tumor-specific
25%
T Cells
25%
Tyrosine Kinase Inhibitor
25%
Bone Marrow Cells
25%
Tumor Antigen
25%
Promising Strategies
25%
CD4+ T Cells
25%
Antigen-specific T Cells
25%
Immunization
25%
Vaccine Effectiveness
25%
T-cell Tolerance
25%
Tumor Antigen-specific T Cell
25%
Tumor-bearing Host
25%
Medicine and Dentistry
Neoplasm
100%
Cell Function
100%
Antigen Presenting Cell
100%
Imatinib
100%
T-Helper Cell
100%
Sexually Transmitted Infection
100%
T-Cell Tolerance
100%
T Cell
50%
Tumor Antigen
50%
Malignant Neoplasm
25%
Immunotherapy
25%
In Vitro
25%
Specific Tumor
25%
Tyrosine-Kinase Inhibitor
25%
Antigen Specificity
25%
Tumor Vaccine
25%
Vaccine Efficacy
25%
Biochemistry, Genetics and Molecular Biology
Imatinib
100%
T Cell
100%
Cell Function
100%
CD4
100%
Antigen Presenting Cell
100%
Tumor Antigen
40%
Antigen Specificity
20%
Tyrosine Kinase Inhibitor
20%
Immunology and Microbiology
Antigen-Presenting Cell
100%
T-Helper Cell
100%
T-Cell Tolerance
100%
T Cell
50%
Tumor Antigen
50%
Antigen Specificity
25%
Immunotherapy
25%
Tyrosine
25%
Tumor Vaccine
25%
Vaccine Efficacy
25%
In Vitro
25%